Alivus Life Sciences Share Price: What Could the Next 3 Years Look Like?

The Alivus Life Sciences share price forecast for the next 3 years is a question on many investors’ minds as the stock trades at Rs 1,169, within a 52 week range of Rs 819 to Rs 1,194. This article lays out a scenario based Alivus Life Sciences share price outlook for 2027, 2028 and 2030, built on the company’s fundamentals, sector trends and the key risks that could change the trajectory. Rather than a single number, the focus here is on the range of outcomes and the assumptions behind each one.

Click Here – Get Free Investment Predictions

Alivus Life Sciences Company Overview

Alivus Life Sciences, formerly Glenmark Life Sciences, is a leading manufacturer of active pharmaceutical ingredients serving generic drug makers globally, now under Nirma Group ownership after the 2023 acquisition. Understanding the business model is the first step in framing any credible Alivus Life Sciences share price forecast, because the durability of earnings ultimately decides where the stock trades.

Company	Alivus Life Sciences
NSE Ticker	ALIVUS
CMP	Rs 1,169
52 Week High	Rs 1,194
52 Week Low	Rs 819
Market Cap	Rs 14,354 Cr
Stock PE	40.8
Book Value	Rs NA
ROE	NA
ROCE	NA
Dividend Yield	0.43%

Where Does Alivus Life Sciences Share Price Stand Today?

The stock trades close to its 52 week high of Rs 1,194, indicating strong recent momentum. A Alivus Life Sciences share price forecast built from these levels must assume earnings keep pace with expectations, and the Alivus Life Sciences share price forecast becomes more sensitive to disappointments, since elevated starting valuations can cap medium term returns.

At the current price, Alivus Life Sciences commands a market capitalisation of Rs 14,354 Cr and trades at a price to earnings multiple of 40.8. The company generates a return on equity of NA and a return on capital employed of NA, which places it in the category of businesses with a recovering profitability profile. These numbers anchor the Alivus Life Sciences share price forecast scenarios that follow. How the broader Nifty 50 index trades over this period will also influence the multiple investors are willing to assign to the stock.

Alivus Life Sciences Share Price Forecast: Key Growth Drivers for the Next 3 Years

Four forces are likely to shape the Alivus Life Sciences share price forecast between now and 2030, and together they explain most of the dispersion in this Alivus Life Sciences share price forecast. Each is discussed below with its likely direction of impact.

Earnings Trajectory and Return Ratios

Stock prices ultimately follow earnings. With a recovering profitability profile at present, the pace at which profits compound over FY27 to FY30 will be the single biggest determinant of the Alivus Life Sciences share price forecast actually playing out. Consistent earnings delivery tends to expand valuation multiples, while misses compress them quickly.

Structural Tailwinds in Indian Pharmaceuticals

The Indian pharmaceutical market continues to grow in high single to low double digits, supported by chronic disease prevalence, better diagnosis rates and premiumisation of therapies. Companies with strong brand equity and field force productivity, like Alivus Life Sciences, are positioned to grow ahead of the market. Sector trends are visible in the Nifty Pharma index, which serves as a useful barometer for the space.

Within the space, investors often benchmark Alivus Life Sciences against peers such as Divis Laboratories, Laurus Labs and Aarti Pharmalabs on growth and valuations before forming a view on the Alivus Life Sciences share price forecast.

Company Specific Catalysts

The bull case for Alivus Life Sciences rests on rising global API demand, new molecule additions and margin improvement under new ownership. If these play out on schedule, the Alivus Life Sciences share price forecast for 2030 could gravitate toward the upper end of the scenario range discussed below.

Macro Environment and Liquidity

The RBI rate cycle, FII flows into Indian equities and overall market valuations will influence the multiple investors are willing to pay. A benign macro backdrop supports the optimistic end of any Alivus Life Sciences share price forecast, while global risk aversion would do the opposite to the Alivus Life Sciences share price outlook.

Alivus Life Sciences Share Price Forecast 2027, 2028 and 2030: Scenario Analysis

The table below presents a scenario based Alivus Life Sciences share price forecast using compounded annual growth assumptions applied to the current market price of Rs 1,169. These are illustrative ranges, not point predictions, and actual outcomes can fall outside them.

Year	Bear Case	Base Case	Bull Case	Assumption
2027	Rs 1,200	Rs 1,310	Rs 1,420	2% to 14% CAGR on CMP
2028	Rs 1,230	Rs 1,420	Rs 1,620	2% to 14% CAGR on CMP
2030	Rs 1,280	Rs 1,650	Rs 2,110	2% to 14% CAGR on CMP

In the base case scenario of this Alivus Life Sciences share price forecast, the 2030 level works out to roughly Rs 1,650, implying steady compounding from today’s levels. The bull case of Rs 2,110 assumes rising global API demand delivers ahead of expectations, while the bear case of Rs 1,280 captures a scenario where growth stalls. That is an outcome band of about 9 percent to 80 percent over the period.

Consult a SEBI Registered Investment Advisor Before Acting on Any Forecast

Bull Case vs Bear Case for Alivus Life Sciences Share Price

The Bull Case

The optimistic Alivus Life Sciences share price forecast assumes rising global API demand, new molecule additions and margin improvement under new ownership. Combined with supportive sector conditions, this could lift both earnings and the valuation multiple, pushing the stock toward Rs 2,110 by 2030.

The Bear Case

The cautious view centres on the fact that API pricing is competitive globally and client concentration among a few large generic makers is a risk. If these pressures dominate, the Alivus Life Sciences share price forecast would skew toward the lower band and the stock could stagnate near Rs 1,280 even by 2030, underperforming broader indices.

Key Risks That Could Change the Alivus Life Sciences Share Price Outlook

• Execution risk: Delays in strategy execution or capacity plans would push the earnings trajectory below the base case assumed in this Alivus Life Sciences share price forecast.
• Valuation risk: At a PE of 40.8, any earnings disappointment can trigger sharp multiple compression before fundamentals stabilise.
• Sector risk: API pricing is competitive globally and client concentration among a few large generic makers is a risk.
• Macro risk: A global slowdown, adverse FII flows or unexpected rate moves would compress equity valuations across the market.
• Regulatory risk: Policy, tax or compliance changes affecting the sector can alter the earnings outlook with little warning.

Is Alivus Life Sciences Worth Watching for the Long Term?

For long term investors, the relevant question is not just where the Alivus Life Sciences share price forecast lands in 2030 or what any single Alivus Life Sciences share price forecast says today, but whether the business can compound capital through cycles. The company’s positioning around rising global API demand gives it a credible growth story, while the risks outlined above define what must be monitored each quarter.

Investors should track quarterly earnings, management commentary and sector data rather than anchoring to any single number from a Alivus Life Sciences share price outlook. Historically, staying focused on business fundamentals has served investors better than chasing price targets, and consulting a SEBI registered advisor before investing remains the prudent approach.

Download the Univest iOS App or Univest Android App to track Alivus Life Sciences share price live.

Conclusion

The Alivus Life Sciences share price forecast for the next 3 years spans Rs 1,280 to Rs 2,110 by 2030 under the scenarios discussed, with a base case near Rs 1,650. Any credible Alivus Life Sciences share price forecast must be updated as facts change, and the path will be decided by earnings delivery, rising global API demand and the broader market environment. Treat these ranges as a framework for thinking, not a promise of outcomes, and revisit the assumptions as new results come in. Consult a SEBI registered investment advisor before making any investment decision.

What is the Alivus Life Sciences share price forecast for the next 3 years?

Ans. The Alivus Life Sciences share price forecast for the next 3 years is scenario based rather than a single number. By 2030, the illustrative range spans Rs 1,280 in the bear case to Rs 2,110 in the bull case, with a base case near Rs 1,650, depending on earnings delivery and market conditions.

What is the Alivus Life Sciences share price forecast for 2027?

Ans. For 2027, the scenario range works out to Rs 1,200 to Rs 1,420, with a base case around Rs 1,310. This assumes compounding on the current price of Rs 1,169 and is illustrative, not a guaranteed outcome.

What is the Alivus Life Sciences share price forecast for 2028?

Ans. The 2028 scenario range is Rs 1,230 to Rs 1,620, with the base case near Rs 1,420. Actual levels will depend on earnings growth, sector trends and overall market valuations at the time.

What is the current share price of Alivus Life Sciences?

Ans. Alivus Life Sciences currently trades at around Rs 1,169 on the NSE, within a 52 week range of Rs 819 to Rs 1,194. Prices change continuously during market hours, so check live quotes before acting.

Is Alivus Life Sciences a good stock for the long term?

Ans. Alivus Life Sciences has a credible long term story built on rising global API demand, but it also carries risks since API pricing is competitive globally and client concentration among a few large generic makers is a risk. Long term suitability depends on your risk profile and portfolio, so consult a SEBI registered investment advisor before investing.

What is the Alivus Life Sciences share price outlook for 2030?

Ans. The Alivus Life Sciences share price outlook for 2030 spans Rs 1,280 to Rs 2,110 across bear and bull scenarios. Where the stock actually lands will be driven by profit growth, valuation multiples and macro conditions closer to that date.

What are the key risks to the Alivus Life Sciences share price forecast?

Ans. The main risks are execution delays, valuation compression from the current PE of 40.8, sector specific pressures, macro shocks and regulatory changes. Any of these can push the stock below the base case scenario discussed in this article.